FDA approves AZ Imfinzi in new lung cancer use

AstraZeneca has reported a double win after the FDA approved its Imfinzi for a form of lung cancer, and it stopped a trial of its Farxiga after showing “overwhelming efficacy” in chronic ki

AstraZeneca: pharma needs to lead by example on sustainabili...

Paul Tunnah sat down with AstraZeneca's vice president of sustainability strategy and engagement Jim Massey to discuss how the global pharma company is embracing a green future.

AstraZeneca forges alliance with digital health firm BrightI...

AZ adds gene silencing tech to pipeline with Silence Therape...

AstraZeneca has announced a collaboration with UK biotech Silence Therapeutics to develop gene silencing drugs for cardiovascular, renal, metabolic and respiratory diseases.

Pharma steps up as coronavirus cases soar to 400,000-plus

FDA backs Glenmark's rival to AZ's blockbuster Farxiga

AstraZeneca’s diabetes drug Farxiga could face generic competition in the US, after the FDA gave tentative approval to a generic rival from India’s Glenmark, although it is unclear when the